These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12817195)

  • 21. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II begins for T-20.
    AIDS Patient Care STDS; 1999 Sep; 13(9):567-8. PubMed ID: 10813040
    [No Abstract]   [Full Text] [Related]  

  • 23. [HIV infections: further options for combination therapy].
    Hildegard K
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1523. PubMed ID: 12899165
    [No Abstract]   [Full Text] [Related]  

  • 24. Long path to approval. A look back at the road to Fuzeon.
    GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
    van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM
    Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.
    Loutfy M; Ribera E; Florence E; De Wit S; Castagna A; Ryan R; Hill A; Vanaken H; van Delft Y; Marks S
    J Antimicrob Chemother; 2009 Dec; 64(6):1341-4. PubMed ID: 19828488
    [No Abstract]   [Full Text] [Related]  

  • 28. [Enfuvirtide desensitisation: due to a failed case].
    López-de-Torre Querejazu A; Ibarra Barrueta O; Santos Ibañez A; Mayo Suárez J
    Farm Hosp; 2012; 36(2):112-3. PubMed ID: 22024011
    [No Abstract]   [Full Text] [Related]  

  • 29. Three new drugs approved by FDA.
    Hoyt G
    Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579
    [No Abstract]   [Full Text] [Related]  

  • 30. First fusion inhibitor for advanced HIV.
    Am J Nurs; 2003 Jul; 103(7):64F. PubMed ID: 12877130
    [No Abstract]   [Full Text] [Related]  

  • 31. [FDA approved the first of a new class of antiretrovirals for adults and children with advanced HIV infection].
    Rev Panam Salud Publica; 2003 Jul; 14(1):57-8. PubMed ID: 12952609
    [No Abstract]   [Full Text] [Related]  

  • 32. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].
    Blasko M
    Dtsch Med Wochenschr; 2003 May; 128(19):1032. PubMed ID: 12774800
    [No Abstract]   [Full Text] [Related]  

  • 34. HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.
    Grossman H
    AIDS Treat News; 2002 Sep; (383):2-7. PubMed ID: 12765126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formal approval for Fuzeon.
    AIDS Patient Care STDS; 2004 Dec; 18(12):736. PubMed ID: 15659885
    [No Abstract]   [Full Text] [Related]  

  • 36. Enfuvirtide for prophylaxis against HIV infection.
    Cuzin L; Alvarez M
    N Engl J Med; 2003 Nov; 349(22):2169-70; author reply 2169-70. PubMed ID: 14645649
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough.
    Meyohas MC; Lacombe K; Carbonne B; Morand-Joubert L; Girard PM
    AIDS; 2004 Sep; 18(14):1966-8. PubMed ID: 15353987
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical perspective of fusion inhibitors for treatment of HIV.
    Rockstroh JK; Mauss S
    J Antimicrob Chemother; 2004 May; 53(5):700-2. PubMed ID: 15044424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.